Table 1.

Patient demographic and baseline characteristics

CharacteristicArm A (n = 23)Arm B (n = 16)Arm C (n = 6)
Sex, no. (%)
    Women7 (30)6 (38)3 (50)
    Men16 (70)10 (63)3 (50)
Median age, y (range)64 (39-79)58 (32-76)60 (56-64)
Race, no. (%)
    White22 (96)14 (88)5 (83)
    Black1 (4)1 (6)0 (0)
    Asian0 (0)1 (6)1 (17)
Disease stage, no. (%)
    Stage IIIB4 (17)3 (19)1 (17)
    Stage IV19 (83)13 (81)5 (83)
No. of sites of disease,* no. (%)
    02 (9)2 (13)0 (0)
    119 (83)11 (69)5 (83)
    22 (9)3 (19)1 (17)
Histologic subtype, no. (%)
    Adenocarcinoma12 (52)10 (63)5 (83)
    Bronchoalveolar carcinoma0 (0)1 (6)0 (0)
    Large cell carcinoma2 (9)0 (0)0 (0)
    Squamous cell carcinoma1 (4)1 (6)0 (0)
    Other8 (35)4 (25)1 (17)
ECOG performance status, no. (%)
    08 (35)4 (25)1 (17)
    115 (65)12 (75)5 (83)
Median time since initial diagnosis, y (range)0.1 (0-3.9)0.7 (0.1-3.7)0.1 (0-0.1)
Time since last prior therapy, mo (range)0.7 (0.5-15.1)3.7 (0.5-213.0)0 (0)
Prior therapy for lung cancer, no. (%)
    Any therapy10 (43)15 (94)0 (0)
    Prior chemotherapy0 (0)14 (88)0 (0)
    Prior radiotherapy4 (17)8 (50)0 (0)
    Prior other therapy6 (26)6 (38)0 (0)
Tobacco use, no. (%)
    Never4 (17)4 (25)0 (0)
    Former16 (70)9 (56)6 (100)
    Current3 (13)3 (19)0 (0)

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

  • *As assessed by investigator.

  • Includes all therapies for lung cancer received before study enrollment.